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Abstract
We examined the current literature to understand factors that influence endocrine therapy (ET) 
adherence among racial/ethnic and socioeconomic subpopulations of breast cancer patients. We 
searched PubMed and PsycINFO databases for studies from January 1, 1978, to June 20, 2014, 
and January 1, 1991, to June 20, 2014, respectively, and hand-searched articles from relevant 
literature reviews. We abstracted and synthesized results within a social ecological framework.
Fourteen articles met all inclusion criteria. The majority of included articles reported significant 
underuse of ET among minority and low-income women. Modifiable intrapersonal, interpersonal, 
and community-level factors are associated with ET use, and these factors vary across subgroups.
Both race/ethnicity and socioeconomic status are associated with ET use in most settings. 
Variation in factors associated with ET use across subgroups indicates the need for more nuanced 
research and targeted interventions among breast cancer patients.
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Low medication adherence is common among patients taking oral drugs; an estimated half 
of all patients are nonadherent to a medication regimen across multiple chronic disease 
areas.1 This low medication adherence is problematic because it is associated with poorer 
prognosis for many common conditions.2 Evidence has demonstrated that non-White 
patients are less likely to adhere to medication regimens than White patients,3,4 suggesting 
that medication adherence may be an important lever for targeting racial disparities in health 
care outcomes. Medication adherence has become a particularly important issue in cancer 
care because the use of oral anticancer drugs in clinical practice has increased.3 Endocrine 
therapy (ET) for breast cancer is among the most common oral anticancer therapies, and 
racial variation in ET adherence may play a role in racial disparities in breast cancer care 
outcomes.
Breast cancer is the most common cancer among women in the United States: of the 232 
570 women diagnosed with invasive breast cancer each year, approximately three quarters 
will have hormone receptor–positive breast cancer.5,6 Typically, women with this type of 
breast cancer undergo surgery with or without radiation, some will take adjuvant 
chemotherapy, and nearly all will be eligible for ET.7,8 ET is most commonly given in the 
adjuvant setting to prevent recurrence of curable cancers.5,9 ET consisting of at least a 5-
year course of tamoxifen or an aromatase inhibitor (AI), is the gold standard for adjuvant 
treatment of these cancers, and it reduces 5-year breast cancer recurrence by 40% and breast 
cancer mortality by one third.10
However, evidence from observational and patient-reported sources has suggested that many 
women underuse ET because of noninitiation (i.e., never starting ET), nonadherence (i.e., 
not taking ET as prescribed), or nonpersistence (i.e., not taking ET for the recommended 
duration).11–15 ET underuse is associated with shorter time to recurrence, lower quality of 
life, and increased medical costs.16 Approximately one third of women who initiate adjuvant 
tamoxifen discontinue the drug before the 5-year, guideline-recommended duration.12,13,15 
Of those who continue taking tamoxifen, 16% to 28% do not fully adhere to the 
therapy.12,13,17–19 Furthermore, adherence and persistence decline over time.19 Thus, by the 
end of the 5-year course of therapy, only about half of women have taken tamoxifen as 
prescribed.12,13 AI data have shown similar patterns of underutilization;12 at 5 years, 19% to 
25% of women have discontinued their AI,20,21 and 20% to 31% of women have been 
nonadherent.18,22
Minority populations may be disproportionately affected by ET noninitiation, 
discontinuation, and nonadherence.12,23–28 Minority and low-income populations are less 
likely to be integrated into the health care system; thus, they may face unique barriers to 
care, such as poor access to providers, that influence receipt of ET and other cancer-related 
treatment.29,30 Among minority women who are also low income or who experience high 
levels of social stressors, competing social and economic demands may take priority over 
medication adherence, leading to suboptimal medication use.31 Patterns of ET utilization 
among minority women are understudied and may contribute to the well-recognized and 
persistent racial, ethnic, and socioeconomic disparities in outcomes. Despite advances in 
breast cancer prevention and treatment, breast cancer mortality remains 37% higher among 
Black women than among White women.32 Biological differences are important but cannot 
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fully explain this racial/ethnic variation in mortality.9,33 Thus, the observed disparities likely 
arise from a combination of factors, including incomplete or omitted ET treatment.
In several studies of insured women, non-White race11,12,22,24–28 and low socioeconomic 
status (SES)34 have been associated with lower ET initiation, adherence, and persistence; 
however, reasons for this variation have not been well described. Although previous 
literature reviews have described factors that are associated with ET utilization broadly, 
none have detailed racial variation in the use of ET. We addressed this literature gap by 
conducting a systematic review of the adjuvant ET literature that is focused on barriers to 
ET use among low-income and minority populations.
METHODS
Our review methods followed Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines (Figure 1).35
Data Sources and Searches
We conducted systematic literature searches of the PubMed and PsycINFO databases for 
articles dated January 1, 1978, to June 20, 2014, and January 1, 1991, to June 20, 2014, 
respectively. We also hand searched the bibliographies of relevant literature (Figure 1).
The precise search terms used for all searches were as follows: (breast cancer[MeSH 
Terms]) AND (aromatase inhibitor* OR tamoxifen[MeSH Terms]) AND (adherence OR 
compliance OR persistence OR maintenance OR discontin* OR initiat*). We chose broad 
search terms to capture all ET utilization articles, including all types of ET (e.g., tamoxifen 
and AIs) and utilization terms (e.g., initiat*, persist*, adhere*). To complement these 
searches, we hand-searched bibliographies of key studies and other relevant review articles 
to identify additional articles that were not captured in the database searches.9,21,22,34,36–72
Study Selection
Studies with both experimental and nonexperimental study designs, with or without a 
comparison group, were included. We included studies that explored both (1) racial/ethnic 
or socioeconomic variation in ET initiation, adherence, or persistence and (2) barriers to ET 
that varied by race/ethnicity or SES through the use of interaction terms for race, ethnicity, 
and SES with other factors (e.g., modifiers) or through analyses of ET use among racial/
ethnic or socioeconomic subgroup populations. Most of these studies used self-reported 
race/ethnicity data.
We excluded studies with the following characteristics:
1. The primary focus was not ET utilization (e.g., efficacy trial data without 
utilization data presented);
2. the study was conducted outside of the United States;
3. ET was delivered as chemoprevention or palliative treatment of metastatic disease;
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4. the article was a literature review, letter to the editor, editorial, or thought piece; 
and
5. the article examined diverse patient populations but did not include racial/ethnic or 
socioeconomic subgroup analyses or interaction terms. We did not exclude studies 
on the basis of duration of follow-up or clinical setting.
We used EndNote X4 (Thompson Reuters, New York, NY), a citation management software 
system, to organize and manage our citation database for the review. EndNote enabled us to 
de-duplicate the individual searches and create a database of unique articles. Using our 
inclusion and exclusion criteria, we conducted title searches to identify which articles should 
undergo abstract review.
Next, 1 author (M. C. R.) reviewed abstracts to determine which articles were eligible for 
full-text review. In this phase, we excluded literature review articles from further analysis; 
however, we hand searched their bibliographies and added relevant references to the abstract 
search.9,36–48 We conducted full-text reviews to determine which articles would be 
abstracted. Study selection and review were conducted by 1 reviewer (M. C. R.). However, 
if the decision to include an article was unclear after the full-text review, a second reviewer 
(S. B.W.) assessed the article, and the final inclusion decision was resolved by discussion 
and consensus between the 2 reviewers.
Data Extraction
Applying the PICOTS framework,73 1 author (M. C. R.) extracted the following data from 
each article: population, intervention (i.e., types of ET included), comparator group (if 
applicable), outcomes, timing (duration of follow-up), and setting. We categorized study 
outcomes into 4 groups: provider discussion, recommendation, and prescribing; initiation; 
adherence; and persistence.
Definitions of utilization varied from study to study. Thus, we classified ET use outcomes 
according to our prespecified definitions of initiation, adherence, and persistence. For the 
purposes of this review, we defined ET initiation, or initial ET use, as whether the patient 
began ET. ET adherence referred to whether the patient took the prescription at the 
recommended dose and on the recommended schedule. Typically, studies defined 
nonadherence as having less than 80% of days covered by prescription fill records. Finally, 
persistence or continuation referred to whether the patient continued to take the medication 
for the recommended duration of therapy (regardless of whether the patient took it correctly 
according to recommended dosing and schedule).We further divided these groups by ET 
type (i.e., amoxifen, AIs, or both). AIs included letrozole, anastrozole, or exemestane.
Data Synthesis and Analysis
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4. independent variable measurement,
5. duration of follow-up, and
6. study setting.
This was a qualitative decision made after data extraction and review. However, we did 
analyze studies within a well-known theory-driven conceptual framework, the social 
ecological framework.74
The ecological perspective of the social ecological framework acknowledges that multiple-
level factors in the social system (i.e., intrapersonal, interpersonal, and community factors) 
influence health behaviors such as ET utilization (Figure 2).75,76 Findings from the 
abstracted articles were organized into intrapersonal, interpersonal, and community levels. 
We report descriptively on the included studies and their implications. Results from 
regression analyses and P values were abstracted directly from the included studies.
RESULTS
Of 142 abstracts, 14 articles met final inclusion criteria (Table 1).19,22,60,77–87 Five of these 
studies examined socioeconomically disadvantaged populations. These 5 studies included 
publicly insured patients who were enrolled in state Medicaid programs19,60,81,87 or 
Medicare’s low-income subsidy program.22 Of all included articles, 677,78,80,81,83,86 
examined primary data collected through the use of surveys, interviews, or focus groups; of 
these, 377,80,83 included self-reported barriers to care (Table 2). Eight 
studies19,22,60,79,82,83,85,87 used large secondary data sources or medical records to examine 
racial/ethnic and socioeconomic disparities in ET use; of these, 377,79,86 examined adjuvant 
breast cancer therapy broadly, including not only ET use but also either chemotherapy, or 
chemotherapy with radiation therapy. Although these studies evaluated chemotherapy and 
radiation therapy as dependent variables, some studies included these treatment variables 
(i.e., surgery, chemotherapy, radiation) as predictor variables of ET use19,22,60,81,82,84,87 and 
other studies78,80,83, did not include treatment variables in their analyses. One study 
stratified results by chemotherapy receipt.85 Finally, of all included studies, only 1 used a 
qualitative approach.77
Intrapersonal Characteristics
Multiple intrapersonal characteristics were associated with ET use: race/ethnicity, 
medication side effects, patients’ health beliefs, and cost of medications, as well as other 
person-level characteristics.
Overall effect of race/ethnicity on endocrine therapy use—The effect of race/
ethnicity on ET use varied by study; however, the majority of the studies indicated that there 
was significant racial/ethnic variation in ET use (Table 3). Several studies indicated that 
Black women had lower odds of initiating ET77,79,85 and being adherent to ET19,22 than 
other racial/ethnic groups. One study found no significant racial/ethnic differences in ET 
persistence by race/ethnicity; however, the authors did note racial/ethnic variation in 
reported barriers to care.83 For example, the most commonly cited barrier to ET use among 
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minorities was lack of physician recommendation, and this barrier was more commonly 
reported among Black women (17%) than among Hispanic women (3%; P = .038).83 In 
another study, although being Black was not associated with ET adherence among women 
receiving the Medicare low-income subsidy, among those who did not receive this subsidy, 
Black women had increased odds of being non-adherent to tamoxifen (odds ratio [OR] = 
2.60; 95% confidence interval [CI] = 1.39, 4.87) and increased odds of being nonadherent to 
an AI (OR = 1.86; 95% CI = 1.35, 2.55) compared with White women.22
Among high-risk patients (defined as women with increased genetic susceptibility to breast 
cancer; e.g., bilateral breast cancer before age 50 years), no racial/ethnic differences 
emerged in ET initiation; however, the opposite was true for women with sporadic (non–
high-risk) breast cancer—Black women had lower odds of initiating ET (OR = 0.20; 95% CI 
= 0.06, 0.60) and non-Hispanic White women had lower odds of using ET (OR = 0.40; 95% 
CI = 0.17, 0.94) than Asian women.84 This same study demonstrated that racial/ethnic 
differences in ET use decreased as the diffusion of ET into clinical practice increased over 
time.84
Hispanic or Latina ethnicity was also associated with differential ET use in certain studies, 
but the direction of association varied by study. Compared with non-Hispanic Whites, low-
income Latina women participating in the California Breast and Cervical Cancer Treatment 
Program were more likely to be persistent with ET at 36 months if they were less 
acculturated (adjusted odds ratio [AOR] = 9.08; P = .001), where acculturation was defined 
as being more comfortable with the English language.81 Interestingly, this association 
between ethnicity and persistence was nonsignificant among Latina women who were more 
acculturated. Other studies, which were not conducted in low-income study populations 
specifically, found that Hispanic women were less likely to initiate adjuvant therapy than 
non-Hispanic White women.79,82 Specifically, 1 study82 indicated that Hispanic women had 
decreased odds of ET initiation compared with White women (AOR = 0.82; CI = 0.71, 
0.96). Asian race was also associated with ET use. One quantitative study82 found that 
Chinese patients had 22% lower odds of initiating ET compared with White patients, and 
one qualitative study77 also indicated lower ET initiation among Chinese women compared 
with other racial/ethnic minorities.
Several studies, however, did not find an association between race/ethnicity and ET use. 
Although a New Jersey Medicaid study indicated lower odds of adherence among non-
Whites compared with Whites,19 2 studies conducted within a North Carolina Medicaid 
population found no association between race/ethnicity and initiation,60,87 adherence,60 or 
persistence.60 Instead, these studies demonstrated low ET use across the board among low-
income women in North Carolina. Another study found no racial differences in ET 
adherence; however, this was a small study conducted in 1 academic medical center.78 The 
authors noted that low power and high insurance coverage rates among Black women in the 
study may explain the nonsignificant findings.78 A study using self-report and Surveillance, 
Epidemiology, and End Results registry data (Los Angeles, CA, and Detroit, MI, regions) 
found that race was not associated with persistence; furthermore, the study found that Black 
and Latina women were more likely to initiate ET than Whites.80 The authors suggested that 
peer support, patient navigator programs, and other important contextual factors may explain 
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improved ET use among Black and Latina women.80 Overall, variation in the effect of race/
ethnicity on ET use likely arises from variation in study designs, populations, ET types, 
outcomes and measurement of other variables, and settings.
Side effects—Side effects were strongly associated with ET use across quantitative and 
qualitative studies. Among low-income women, those who experienced side effects had 
lower odds of persistence at 36 months (AOR= 0.26; P = .003; Table 4).81 Furthermore, side 
effects emerged as an important concern during patient focus groups.77 In particular, 
changes in body image and sexual concerns as a result of ET use were noted as common 
concerns across all racial/ethnic groups.77 In 1 study, fear of side effects was reported as a 
barrier among 28.8% of noninitiators: 40%of women who discontinued therapy reported 
side effects a reason for discontinuation, and 25%of women who discontinued therapy 
reported being worried about risks associated with ET.80
Racial/ethnic variation existed in the reporting of side effects as a barrier to ET use. For 
example, in 1 study, the most commonly cited barrier to ET use among Hispanic patients 
was side effects, whereas side effects were the least commonly cited barrier among Black 
women (16% vs 8%; non-significant).83 Regardless of racial/ethnic variation in reporting, 
however, side effects were among the top reported barriers to ET.83 Interestingly, 1 small 
prospective study did not find an association between concerns about side effects and ET 
adherence; this study instead found a positive association with ET adherence when women 
reported increased value in their provider’s opinion and when women had a higher perceived 
importance of ET, suggesting these factors may be the drivers for ET adherence, not 
concerns about side effects.78
Health beliefs—Several health beliefs were associated with ET use. Higher perceived 
efficacy of patient–physician interactions was associated with increased ET persistence 
among low-income women (OR = 1.04; P = .04).81 Worry about recurrence was associated 
with increased odds of ET initiation; however, this association was not found with ET 
persistence,80 suggesting that different factors influence different types of ET behavior.
A dislike for medication (23.2%), being unsure whether ET was helping (22.3%), feeling as 
though they had taken ET long enough (17.9%), and wanting to move on from cancer 
(16.1%) were all reported reasons for discontinuing ET by 4 years.80
Endocrine therapy–related costs—Costs were reported as a barrier to ET use across 
racial/ethnic groups in both qualitative and quantitative studies. Out-of-pocket costs among 
Medicare beneficiaries influenced ET use regardless of ET type and SES (including both 
patients who received low-income subsidies and those who did not across racial/ethnic 
groups).22 In a qualitative study, financial burden and access to affordable breast cancer care 
were recurring themes among both key informants (i.e., community health workers and 
advocates in diverse breast cancer populations) and breast cancer survivors.77
In particular, Latinas noted job disruptions and financial hardships as barriers to ET 
initiation and adherence.77 However, another study found that cost was a barrier to ET use 
among only 5% of women.83 In yet another study, costs were rarely reported as a reason for 
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noninitiation (5%); however, cost was reported more often as a reason for discontinuation 
among women who stopped ET before 4 years of therapy (18.8%), and a small proportion 
stopped for insurance-related reasons (7%).80 Thus, it is unclear to what extent costs are a 
barrier specific to minorities in the use of ET across settings and populations. Variation in 
results regarding cost may be explained by changes in generic availability for tamoxifen and 
AIs over time during the different study periods.
Other person-level characteristics—Associations between other person-level 
characteristics and ET use were also observed. Education was not associated with ET use 
among a diverse, low-income population.81 However, in a qualitative study, Latinas 
reported that, broadly, low education and language presented barriers to breast cancer 
care.77 These differences may be explained by the inclusion of provider–patient 
communication factors, potentially suggesting that good communication, not education 
level, influences ET use.
Mixed evidence was found regarding associations between ET use and age, income, health 
care utilization (e.g., number of office visits), prescription use (e.g., number of other 
prescriptions), insurance status, clinical characteristics, tumor characteristics, and treatment 
characteristics. This variation is likely the result of variation in study designs and analysis 
methods, patient populations and settings, and ET use measures.
Interpersonal Characteristics
Several interpersonal characteristics were associated with ET use. In particular, studies 
reported that provider referral, patient–provider communication, and social support played a 
role in the use of ET.
Provider referral and recommendation—One study investigated the relationship 
between receiving a referral to a medical oncologist, race/ethnicity, and ET use.79 Race/
ethnicity was not associated with receiving a medical oncologist referral.79 Furthermore, 
among women who saw a medical oncologist, race/ethnicity was not associated with receipt 
of adjuvant therapy (including radiation, chemotherapy, or ET). However, among women 
who did not see a medical oncologist, racial/ethnic differences in receipt of adjuvant 
therapies persisted, in that non-Hispanic White women were more likely to use ET than non-
Hispanic Black or Hispanic White women.
Overall, these results suggest that referral to a medical oncologist may ameliorate disparities 
in the use of appropriate breast cancer care, perhaps by bridging knowledge gaps or provider 
network gaps through medical oncology consultation.79 Another study indicated that women 
whose primary oncology provider was a medical oncologist had a higher likelihood of ET 
initiation than those whose primary provider was a surgeon; this association did not hold for 
ET persistence.80 The authors suggested that patients who see a medical oncology provider 
may have clearer indications for ET use than those who see a surgeon or other provider, 
which may explain why there were differences in ET initiation by provider type, but not in 
persistence.80
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Among ET-eligible women who did not initiate ET, 33.8% reported not taking ET because 
their provider said they did not need to, because the doctor left the decision up to them 
(21.3%), or because the doctor never discussed ET (7.5%).80 However, some women 
reported not initiating ET despite a doctor’s recommendation (18.8%).80 Finally, of women 
who discontinued ET, 25% who stopped within 4 years after ET initiation reported doing so 
because of a doctor’s recommendation.80
Patient–provider communication quality—The quality of communication between 
provider and patient appears to influence ET use across qualitative and quantitative studies. 
Patient-centered communication increased ET use among low-income Latina women, where 
patient-centered communication was defined as communication that explores “patients’ 
ideas and concerns, and assesses and responds to their emotions and understanding” (AOR = 
1.22; P = .006).81(p830) The effect of patient-centered communication on ET use did not vary 
by ethnicity in this low-income population.81 Although quality of communication was 
important to patients, this study found that provider–patient discussion specifically about the 
hormonal activity of ET and how ET works biologically was not associated with ET use.81
Results from another survey indicated that communication about ET was rated lower among 
Black patients than among White patients (P ≤ .001).86 Quality of provider communication, 
extent of provider’s involvement, and level of trust in the medical system were all rated 
lowest among Black patients.86 Emergent themes from qualitative interviews and focus 
groups showed that patients and key informants believed there was “an urgent need for 
health care providers to become more culturally sensitive” during patient–provider 
interactions with respect to adjuvant treatment discussions.77(p425) Women who felt they 
received adequate information about ET were more likely to initiate ET than those who did 
not.80
Social support—In our review, we found that social support was not strongly associated 
with ET use. Hispanics (32%) were significantly more likely than were Whites (18%) and 
Asians (13%) to report being helped by parents, children, or grandchildren during ET-
related decision-making, whereas Asians (38%) were more likely than were Blacks (22%) to 
be helped by a husband or partner.86 This information may be important for the small 
minority of patients who indicated that discouragement from family (< 1%) and friends (< 
1%) was a barrier to ET use.83
We should note that although marital status was associated with increased initiation in 1 
study,82 it was not associated with ET adherence among participants receiving a low-income 
subsidy through Medicare,22 and not being married was associated with improved adherence 
(OR = 1.90; P = .006) and persistence (OR = 1.74; P = .031) among North Carolina 
Medicaid participants.60 The authors suggested that this association reflects a different 
pattern of social support among the North Carolina Medicaid population than among other 
populations.60 Variation in findings may reflect not only differences in patient populations 
but also differences in measures of social support. Marital status has been used as a proxy 
for social support; however, it may reflect only a fraction of the social support construct.
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Community factors may also be associated with ET use. During interviews in a qualitative 
study, key informants indicated that “communities must be educated about breast cancer to 
maximize their use of available resources.”77(p412) Also noted was the need for more 
diversity in staff and more partnerships with psychosocial services in the health care system. 
Finally, culturally and linguistically appropriate programs, such as community-based 
support groups and targeted public health programs, were identified as potential 
interventions that may improve quality of care for breast cancer patients.77
In support of this qualitative work, 1 study found that participating in the North Carolina 
Breast and Cervical Cancer Control Program was associated with increased odds of 
initiating ET.87 This program provides free and low-cost breast cancer screening and follow-
up to low-income women. Services are provided at local health departments, community 
health centers, hospitals, and practices across North Carolina. Thus, increasing access to 
public health resources may improve ET use. Other health system–level factors, such as 
hospital size,60 urban versus rural residence,87 and census tract–level income,22 were not 
significantly related to ET use among low-income populations, suggesting that provider-and 
patient-level factors may play a greater role in ET use. However, in 1 North Carolina 
Medicaid study, women who were seen at a small hospital (< 100 beds) had greater odds of 
using any ET than women who were seen at a larger hospital (> 100 beds; OR = 1.49; P = .
024).60 Reasons for this difference were not discussed.
DISCUSSION
Medication initiation, adherence, and persistence remain a challenge for women taking 
adjuvant ET. Generally, medication adherence decreases as the longevity of a drug regimen 
increases.2 Thus, issues surrounding adherence to ET have become even more important 
because evidence has demonstrated the additional benefit of taking ET for as long as 10 
years after hormone receptor–positive breast cancer diagnosis.88 Patterns of nonadherence 
mirror those of other long-term oral medications, with only approximately half of women 
completing ET as prescribed.
Although the evidence is mixed, the vast majority of studies included in this review 
suggested that ET is less optimally used by minorities and that barriers and facilitators to use 
also vary by race/ethnicity and SES. Studies examining adherence and persistence across 
multipayer populations will provide more insight into racial disparities in ET use. Although 
some barriers to care are relevant and cut across all racial/ethnic and socioeconomic 
subgroups (e.g., patient-centered communication, community factors), other barriers seem to 
vary in importance by subgroup and even within subgroups. For example, side effects, less 
education, and lack of physician recommendation were reported as potential barriers to ET 
use at different rates across racial/ethnic groups. At a more granular level, variation in ET 
use existed within racial/ethnic subgroups, such as Latina women with different levels of 
acculturation.
Results also indicated potential interactions between SES and race. In 1 study, the effect of 
cost on ET use did not vary by race among women receiving Medicare low-income 
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subsidies; however, this was not true for women without the subsidy.22 SES has long been 
recognized as a confounding factor for racial/ethnic disparities.31 Competing social and 
economic demands may take priority over medication adherence, resulting in lower 
adherence among those in lower SES groups. Two of the 4 included Medicaid studies found 
no association between ET use and race, which contrasts with findings with more 
socioeconomically diverse populations.
Although race/ethnicity and SES are associated with medication behaviors, the current 
literature suggests that modifiable targets for improving ET exist. These targets include 
intrapersonal characteristics (such as side effect management, health beliefs, and costs), 
interpersonal characteristics (such as provider referral and provider communication), and 
community factors (such as community-based support groups, education, and resources). 
The multidimensional mechanisms behind nonadherence to medication remain complex and 
uncertain; however, this literature review homes in on modifiable barriers to ET use among 
racial/ethnic minority and low-SES subgroups and suggests that interventions to improve ET 
adherence should target these patient-specific modifiable barriers. Discussions in broader 
reviews of medication adherence suggest that the majority of current interventions to 
improve medication adherence have reported relatively small gains.1–3 Thus, there remains a 
need for more innovative, multidimensional, patient-centered, and methodologically sound 
interventions.1–3 The results of this literature review indicate that tailoring interventions to 
racial/ethnic and socioeconomic subgroups may improve ET use.
Looking forward, further disentangling the independent and interactive effects of race/
ethnicity and SES on ET use will be important. Drawing a clear conclusion about their 
effects on ET use remains difficult because the current literature has used heterogeneous 
study designs, populations, and measures. Longitudinal cohort studies and qualitative work 
with providers and patients are needed to assess the role of race/ethnicity in ET initiation, 
adherence, and persistence, as well as to identify unique, multilevel barriers and facilitators 
across racial/ethnic and low-income groups.
This literature review has several limitations. First, we did not rate the quality of each 
included article. The quality of included studies varies, thus individual results should be 
interpreted with caution. Our literature review narrowly focused on racial/ethnic minority 
and low-SES patient populations in the United States; thus, results may not be applicable to 
broader breast cancer patient populations. ET is commonly used among women with 
metastatic breast cancer. We did not examine ET use in this setting; however, to our 
knowledge no such studies have been conducted. Finally, although we conducted a thorough 
systematic literature search in 2 large databases, the possibility remains that our review 
could have missed relevant articles.
To our knowledge, this literature review is the first to examine racial/ethnic and 
socioeconomic disparities in ET initiation, adherence, and persistence. Although other 
literature reviews have examined the broad use of ET,36–48 we have taken a deeper look at 
studies that examined variations in and barriers to ET use among specific racial/ethnic 
minority and low-income patient populations. These results raise awareness of the need for 
(1) more nuanced information on how to overcome barriers to ET use across racial/ethnic 
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and socioeconomic subgroups and (2) development of tailored interventions to improve ET 
use in targeted subpopulations. By further developing knowledge about barriers to ET use 
among racial/ethnic and low-SES subgroups, we can build the evidence required to help 
ameliorate disparities in breast cancer outcomes.
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Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram 
depicting the systematic search strategy.
Note. ET = endocrine therapy; HRT = hormone replacement therapy; SES = socioeconomic 
status.
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Social ecological framework guiding data analysis.
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TABLE 2





  Side effects Side effects were noted as barriers to care.77,80,83 In particular body image and sexual concerns 
emerged as common barriers for women across all racial groups during a qualitative analysis.77 Fear 
of side effects was reported as a reason to not initiate ET among noninitiators (28.8%) and as a reason 
to discontinue (25%) among discontinuers. Also, some noninitiators (18.8%) chose not to initiate ET 
despite provider recommendations.80
  Cost Financial burden and job disruption emerged as barriers to care, with participants noting a need for 
affordable breast cancer care.77 However, in a survey, cost specific to ET was a barrier among only 
5% of patients and insurance was a barrier among only 1% of patients.83 Another study reported a 
small number of women who discontinued ET reported lack of coverage by insurance as a reason for 
discontinuation (7.1%).80 A small proportion of noninitiators (5%) reported that ET was too 
expensive.80 However, a larger proportion of women noted cost as a reason for having discontinued 
ET (18.8%). Furthermore, < 1% of women were concerned about missing work.83
  Education Latina women felt that low education may be a barrier to care.77
  Other Patients infrequently listed inconvenience of use (< 1%) as a barrier to care.83 Some women reported 
disliking medication (23.2%), being unsure whether it was helping(22.3%), feeling as though they had 
taken ET long enough (17.9%) and wanting to move on from cancer (16.1%) as reasons for having 
discontinued ET early.
Interpersonal factors
  Communication Lack of a provider recommendation was the most commonly cited barrier across racial groups; 
however, Black women cited it most often.83 Language was noted as a barrier to communication and 
breast cancer care.77 “Doctor said I did not need” (33.8%), “doctor left it up to me” (21.3%), and 
“doctor never discussed” (7.5%) were reported as reasons for noninitiation among a group of 
noninitiators.80 Patients reported discontinuing ET early because a doctor told them to (25%).80
  Social Discouragement from family (< 1%) and discouragement from friends (< 1%) were given as barriers 
to care.83
Community factors: recommendations Recommendations from focus groups in 1 study primarily target a community-level approach so that 
patients can receive culturally and linguistically appropriate care.77 Furthermore, educating the 
community and increasing cultural sensitivity were recommended to improve breast cancer care for a 
diverse patient population.77
Note. ET = endocrine therapy.
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TABLE 3
Effect of Race on Endocrine Therapy Use Among Eligible Included Studies
First Author Outcome Disparity Data Source Population (% African 
American)
Partridge19 Adherence White > non-White Pharmacy claims NJ Medicaid and NJ PAAD 
program (17%a)
Riley22 Adherence White > African Americanb Pharmacy claims Medicare (6%)
Kimmick60 Initiation No significant association Pharmacy claims NC Medicaid (41%a)
Persistence No significant association
Adherence No significant association
Liu81 Persistence Less acculturated Hispanic > 
White
Self-report CA Medicaid: CA Breast and 
Cervical Cancer Treatment 
Program (6%)
Livaudais82 Initiation NHW > Hispanic, NHW > 
Chinese
Pharmacy claims KPNC (6%)
Livaudais84 Initiation Asian > NHW, African 
Americanc
Self-report NCBCF (11%)
Livaudais83 Initiation, persistence No significant association Self-report WHI study (4%)
Wheeler87 Initiation No significant association Pharmacy claims NC Medicaid (53%a)
Bhatta78 Adherence No significant association Self-report University of Chicago Hospital 
(31.5%)
Persistence Self-report and medical 
record review
Compliance
Reeder-Hayes85 Initiation White > African American Pharmacy claims Privately insured (11%)
Friese80 Initiation African American and Latina > 
White
Self-report LA County and metropolitan 
Detroit SEER regions (14.2%)
Persistence No significant association
Bickell79 Initiation White > Black, Hispanic Medical record review 6 NYC hospitals (21%)
Note. CA = California; LA = Los Angeles; NC = North Carolina; NHW = Non-Hispanic White; NJ = New Jersey; KPNC = Kaiser Permanente of 
Northern California; NCBCF = Northern California Breast Cancer Family Registry; NYC = New York City; PAAD = Pharmaceutical Assistance 




Only among women without the low-income subsidy.
c
Only among women with suspected hereditary breast cancer.
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TABLE 4
Correlates of Endocrine Therapy Initiation, Persistence, and Adherence Among Minority and Low-Income 
Populations and Subpopulations in Included Studies
Correlate Initiation Adherence Persistence
Age
  Older Positive,60,82 NS87,80 Negative,19 NS60 Negative,80 NS81
  Younger Negative19
Married Positive,82 negative60 Negative,60 NS22 Negative,60 NS81
Education NS81
Financial adequacy NS81
Blind or disabled NS87
Comorbidity Negative,82 NS60,85,87 Positive,19 NS60 Positive60,81
High hierarchical condition category (insurance risk) Positive,22 NS22
Preexisting depression NS85
History of estrogen replacement therapy NS19
No. of prescription medications Positive60 NS60 Positive,89 NS60
Hormone receptor positive status Positive60 NS60 NS60
Stage Negative,85 NS80,87 NS,22 positive22 NS80,81
  Grade 2 (vs 1) Positive80,82 NS80
  Grade 3 (vs 1) NS80,82 NS80
Well differentiated (vs poorly) Positive85
Moderately differentiated (vs poorly) Positive85
Unknown differentiation (vs poorly) NS85
Lobular (vs ductal) Positive82
Other nonlobular histology (vs ductal) Negative82
Regional (direct extension or lymph node) vs local Positive60,82 NS60 Positive60
Regional (direct extension and lymph node) vs local NS82
Mastectomy (vs BCS and/or no surgery) Positive,82 NS60,87 Negative,19 NS22,60 NS60,81
BCS no radiation (vs BCS with radiation) Negative85
Mastectomy, no radiation (vs mastectomy with radiation) NS85
Adjuvant chemotherapy Negative,60,85 NS82,87 NS19,60 NS60,81
Radiation Positive,60 NS87 NS19,60 NS60,81
Perceived importance of ET Positive78
Value provider’s opinion Positive78
Concern about side effects NS78
Worry about recurrence Positive80 NS80
Perceived efficacy in patient-provider interactions Positive81
ET side effects Negative81
Out-of-pocket costs Negative22
No insurance Negative81
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Correlate Initiation Adherence Persistence
Insurance plan type (public employee versus other) NS85 NS19,22
Age at Part D enrollment NS22
Breast Cancer Cervical Cancer Control Program (vs Medicaid only) Positive87
Oncology visit within year Positive19
Primary oncology provider: medical oncology (vs surgeon) Positive80 NS80
Patient-centered care Positive81
Discussion about ET NS81
Received enough information about ET Positive80
Use of other prescriptions (nonbaseline) NS19
No. of outpatient visits NS19
Nursing home use NS19
Days of acute hospitalization in prior y NS19
Urban NS60,87 NS22,60 NS60
Small hospital (vs large) Positive60 NS60 NS60
Zip code income ($30 000–$40 000 vs < $30 000) Positive,22 NS22
% county poverty
  Lowest quartile vs high mid NS85
  Lowest quartile vs highest NS85
  Lowest quartile vs low mid Negative85
No. hospitals with oncology services in county
  Lowest quartile vs high mid NS85
  Lowest quartile vs highest NS85
  Lowest quartile vs low mid Negative85
Calendar year Positive,82 negative,87 NS85 Negative,22 NS19,22
Note. BCS = Breast-conserving surgery; ET = endocrine therapy; negative = negative association with outcome (P ≤.05); NS = nonsignificant 
association with outcome (P > .05); positive = positive association with outcome (P ≤.05). Studies that looked at adjuvant breast cancer treatment 
broadly are not included. For studies that looked at racial/ethnic and socioeconomic subpopulations, only multivariable regression results for racial/
ethnic minorities or low-income populations are included in this table.
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